JWH-030
![]()  | |
| Legal status | |
|---|---|
| Legal status | 
  | 
| Identifiers | |
IUPAC name 
  | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H21NO | 
| Molar mass | 291.394 g·mol−1 | 
| 3D model (JSmol) | |
SMILES 
  | |
InChI 
  | |
| (verify) | |
JWH-030 is a research chemical which is a cannabinoid receptor agonist.[1] It has analgesic effects and is used in scientific research.[2] It is a partial agonist at CB1 receptors, with a Ki of 87 nM, making it roughly half the potency of THC.[3] It was discovered and named after John W. Huffman.
In the United States, CB1 receptor agonists of the 3-(1-naphthoyl)pyrrole class such as JWH-030 are Schedule I Controlled Substances.[4]
See also
References
- ↑ Lainton JA, Huffman JW, Martin BR, Compton DR (February 1995). "1-Alkyl-3-(1-naphthoyl) pyrroles: A new class of cannabinoid". Tetrahedron Letters. 36 (9): 1401–4. doi:10.1016/0040-4039(95)00016-6.
 - ↑ Pertwee RG, Griffin G, Lainton JA, Huffman JW (September 1995). "Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens". European Journal of Pharmacology. 284 (3): 241–7. doi:10.1016/0014-2999(95)00318-f. PMID 8666005.
 - ↑ Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME (May 1998). "Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes". The Journal of Pharmacology and Experimental Therapeutics. 285 (2): 553–60. PMID 9580597.
 - ↑ 21 U.S.C. § 812: Schedules of controlled substances
 
| Phytocannabinoids (comparison)  | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endocannabinoids | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Synthetic cannabinoid receptor agonists / neocannabinoids  | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Allosteric CBRTooltip Cannabinoid receptor ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Endocannabinoid enhancers (inactivation inhibitors)  | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Anticannabinoids (antagonists/inverse agonists/antibodies)  | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||
  | |||||||||||||||||||||||||||||||||||||||||||||||||||
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
